Kallman Craig has recently amended its Schedule 13G, revealing a 4.9% ownership stake in PAVmed Inc. This filing, dated October 23, 2026, is significant as it highlights Kallman Craig's ongoing investment strategy in the surgical and medical instruments industry.
The amendment indicates that Kallman Craig beneficially owns 399,752 shares of PAVmed's common stock, reflecting a notable commitment to the company. This stake could potentially influence PAVmed's future decisions and market dynamics, particularly in the competitive landscape of medical instruments.
Background
Kallman Craig is a private entity that has engaged in various investment activities. The company’s recent filing with the SEC identifies its ownership in PAVmed Inc., a company classified under the SIC code for surgical and medical instruments and apparatus. The filing history includes a previous Schedule 13G submitted on April 3, 2026, and an earlier one on December 16, 2025.
What the Filing Says
The Schedule 13G/A filing states, "The Trust beneficially owns 399,752 shares of Common Stock. Mr. Kallman may be deemed to beneficially own the shares of Common Stock held by the Trust, because Mr. Kallman controls the Trust." This indicates that both Kallman Craig and the Craig Kallman 2015 Living Trust hold equal voting and dispositive power over the shares.
Impact
This ownership stake may affect PAVmed Inc.'s strategic decisions and market positioning. With Kallman Craig holding a significant percentage of shares, it may have a voice in shareholder meetings and influence the direction of the company. The filing also suggests that Kallman Craig is committed to its investment in the surgical and medical instruments sector.
What's Next
The filing does not say what happens next.